Released: 18-Nov-2014 10:00 AM EST
Delivering Drugs Inside Aggressive Tumors
Yale Cancer Center/Smilow Cancer Hospital

A multi-disciplinary team of Yale Cancer Center researchers has discovered a promising new method for delivering drugs into aggressive tumors by exploiting a unique feature of tumors themselves. The novel delivery system, described in MicroRNA silencing for cancer therapy targeted to the tumour microenvironment,was published November 17th in the journal Nature.

21-Nov-2014 3:00 PM EST
Quitting Cigarettes Tougher for Heavy-Drinking Smokers, but Phone Counseling Can Help
Yale Cancer Center/Smilow Cancer Hospital

Smokers who drink heavily have a tougher time quitting cigarettes than smokers who drink moderately or not at all. However, a multi-center study led by researchers in Yale Cancer Center and Yale School of Medicine found that modifying tobacco-oriented telephone counseling to help hazardous drinkers can help them quit smoking.

25-Nov-2014 1:00 PM EST
Protein Predicts Response to New Immunotherapy Drug
Yale Cancer Center/Smilow Cancer Hospital

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found. The study, led by a Yale Cancer Center investigator, is described in the Nov. 27 edition of the journal Nature.

Released: 10-Dec-2014 3:00 PM EST
New Drug Combination for Advanced Breast Cancer Delays Disease Progression
Yale Cancer Center/Smilow Cancer Hospital

A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial.

Released: 3-Feb-2015 7:00 PM EST
Study Offers New Look at Complex Head and Neck Tumor Behavior
Yale Cancer Center/Smilow Cancer Hospital

Head and neck squamous cell cancer (HNSCC) ranks among the top ten most prevalent cancers in the United States. Despite its prevalence, little is known about how this cancer develops and spreads. However, in a paper published in the January 29, 2015 edition of Nature, researchers offer critical new information about head and neck cancers.

Released: 4-Feb-2015 1:30 PM EST
Yale Scientist Wins International Award for Discoveries Leading to New Class of Cancer Drugs
Yale Cancer Center/Smilow Cancer Hospital

A Spanish foundation has awarded a major scientific prize to Yale researcher Joseph Schlessinger and two colleagues in recognition of their work leading to the first personalized treatments for cancer. The 2015 Frontiers of Knowledge Award in Biomedicine from the Madrid-based BBVA Foundation includes a €400,000 cash prize.

Released: 4-Feb-2015 4:05 PM EST
New Tool Helps Identify Lung Cancer Patients Who Will Respond to Immune Therapies
Yale Cancer Center/Smilow Cancer Hospital

A Yale-led team of researchers has developed a new assay, or investigative tool, to measure the anti-tumor immune activity in non-small cell lung cancer tumors that could lead to a more accurate determination of which patients will respond to immune therapy drugs. Findings from the study were published in the Journal of the National Cancer Institute.

Released: 7-Apr-2015 12:00 AM EDT
Tiny Hair Follicle Holds Big Clues About the Life and Death of Stem Cells
Yale Cancer Center/Smilow Cancer Hospital

Inside the microscopic world of the mouse hair follicle, Yale Cancer Center researchers have discovered big clues about how stem cells regenerate and die. These findings, reported in the journal Nature, could lead to a better understanding of how the stem cell pool is maintained or altered in tissues throughout the body.

Released: 7-Apr-2015 9:00 AM EDT
Too Much of a Bad Thing Can Be Good in Brain Tumors
Yale Cancer Center/Smilow Cancer Hospital

DNA mutations can cause cancer but in some cases, more mutations may mean a better prognosis for patients. A Yale-led comprehensive genomic analysis of more than 700 brain tumors has revealed one such subtype of the most malignant brain tumor, called glioblastoma, or GBM. This subtype possesses thousands of tumor-specific DNA errors or mutations instead of dozens observed in most glioblastoma cases. It is also associated with longer survival.

Released: 15-Apr-2015 9:05 AM EDT
Yale Launches National Study of Personalized Medicine for Metastatic Melanoma
Yale Cancer Center/Smilow Cancer Hospital

Yale University has launched a multicenter clinical trial, sponsored by Stand Up to Cancer and Melanoma Research Alliance, that will apply the latest in personalized medicine technology to treat metastatic melanoma. The trial, for which Yale is a lead site, will enroll patients lacking a particular genetic mutation for whom immune therapy did not work or was not an option.

17-Apr-2015 2:05 PM EDT
Re-Engineering Lupus Into a Cancer Killer
Yale Cancer Center/Smilow Cancer Hospital

Researchers from the Yale Cancer Center and the Veterans Affairs Greater Los Angeles Healthcare System have devised a way to re-engineer lupus antibodies to turn them into potential cancer killers. Findings from recent research were presented April 21 at the American Association for Cancer Research Annual Meeting 2015 Philadelphia.

17-Apr-2015 3:00 PM EDT
Most Cancer Patients Want Tumor Profiling, Even if It Reveals Other Genetic Risks
Yale Cancer Center/Smilow Cancer Hospital

Most cancer patients would opt for tumor profiling even if the test revealed that they or their families were at risk for other genetic diseases, according to a Yale Cancer Center study. The findings were presented April 21 at the American Association for Cancer Research Annual Meeting 2015 in Philadelphia.

Released: 20-Apr-2015 12:05 PM EDT
Yale Joins Lung Cancer Dream Team
Yale Cancer Center/Smilow Cancer Hospital

Yale Cancer Center will join a group of prominent cancer research and treatment institutions in a new Stand Up To Cancer (SU2C) – American Cancer Society $20 million Dream Team to combat lung cancer.

Released: 18-May-2015 3:45 PM EDT
Yale Cancer Center at 2015 ASCO Annual Meeting
Yale Cancer Center/Smilow Cancer Hospital

Highlights include: new immunotherapy response/survival data for immunotherapy for bladder and lung cancers; advances in small cell lung cancer; exercise and quality of life for cancer survivors; expanding indications for checkpoint blockade

27-May-2015 12:05 PM EDT
Removing More Tissue During Breast Cancer Surgery Reduces by Half the Need for Second Procedure
Yale Cancer Center/Smilow Cancer Hospital

Removing more tissue during a partial mastectomy could spare thousands of breast cancer patients a second surgery, according to a Yale Cancer Center study. The findings were published online May 30 in the New England Journal of Medicine and presented at the 2015 Annual Meeting of the American Society of Clinical Oncology in Chicago.

Released: 11-Aug-2015 1:05 PM EDT
New Simple Proteins Play Active Role in Cellular Function
Yale Cancer Center/Smilow Cancer Hospital

Yale scientists have developed simple new proteins almost devoid of chemical diversity that still play a surprisingly active and specific role in cellular function, causing cells to act like cancer cells, they report Aug. 10 in the Proceedings of the National Academy of Sciences.

   
Released: 1-Sep-2015 9:05 AM EDT
Yale Cancer Center Receives $11 Million From National Cancer Institute for Lung Cancer Research
Yale Cancer Center/Smilow Cancer Hospital

Armed with an $11 million grant from the National Cancer Institute (NCI), Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven will launch a new research program in non-small cell lung cancer, one of the world’s most prevalent and lethal forms of cancer.

Released: 15-Oct-2015 9:05 AM EDT
Rare Mutation May Extend Survival in Lung Cancer Patients with Brain Metastases
Yale Cancer Center/Smilow Cancer Hospital

Most patients with non-small cell lung cancer (NSCLC) that has metastasized to the brain have a dire prognosis. But Yale researchers have identified a subset of those patients with a rare genetic mutation who are living significantly longer than patients without the mutation.

Released: 16-Oct-2015 12:05 PM EDT
Craig Crews, PhD, receives NCI’s Outstanding Investigator Award
Yale Cancer Center/Smilow Cancer Hospital

The National Cancer Institute has named Craig Crews, PhD, a recipient of its Outstanding Investigator Award. Crews, the L. B. Cullman Professor of Molecular, Cellular, and Developmental Biology, was one of 60 US scientists to receive the award, which brings $4.2 million over seven years to support his lab’s research.

Released: 30-Nov-2015 6:05 PM EST
Black Women Less Likely to Benefit From Early Chemotherapy
Yale Cancer Center/Smilow Cancer Hospital

It is well documented that black, Hispanic and Asian women typically develop advanced-stage breast cancer more often than white women. As a result, black women are likelier to receive neoadjuvant chemotherapy, or chemotherapy prior to surgery, in hopes of improving outcomes. However, a Yale Cancer Center study published recently in the Journal of Clinical Oncology found that among minority women treated with early chemotherapy, black women fare worse than the other groups.

3-Dec-2015 6:05 PM EST
New Vaccine Strategy Better Protects High-Risk Cancer Patients From Flu
Yale Cancer Center/Smilow Cancer Hospital

Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza. The findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.

3-Dec-2015 6:05 PM EST
Yale Researchers Find New Pathway Underlying Multiple Myeloma Relapse
Yale Cancer Center/Smilow Cancer Hospital

One of the biggest questions about the treatment of multiple myeloma, a form of blood cancer, is why nearly all patients treated with current therapies eventually suffer relapse. A Yale Cancer Center study may have solved this mystery by identifying how cancer cells escape treatment, leading to recurrence. The findings were presented Dec. 6 at the 57th annual meeting of the American Hematologic Society in Orlando, Florida.

8-Feb-2016 1:05 PM EST
Yale Researchers Link Lipids to One-Third of Myelomas
Yale Cancer Center/Smilow Cancer Hospital

Yale Cancer Center researchers have identified what causes a third of all myelomas, a type of cancer affecting plasma cells. The findings, published in the Feb. 11 issue of the New England Journal of Medicine, could fundamentally change the way this cancer and others are treated.

Released: 12-Feb-2016 2:05 PM EST
Long-Term Cancer Survivors Still Need Guidance About Screening, Side Effects, Lifestyle
Yale Cancer Center/Smilow Cancer Hospital

A team of researchers from Yale School of Public Health and Yale Cancer Center recently published a study in the Journal of Cancer Survivorship that addresses the needs of cancer survivors who are at least nine years beyond an initial diagnosis. In the Q &A below, authors Mary Playdon, Tara Sanft, and Brenda Cartmel, talk about how to better care for long-term survivors.

Released: 29-Feb-2016 3:05 PM EST
Yale Scientists Identify Gene That Regulates the Growth of Melanoma
Yale Cancer Center/Smilow Cancer Hospital

Yale Cancer Center researchers have identified a gene in melanoma that can dramatically affect the growth of the disease. The findings, published in the journal Cell Reports, provide new insight into how melanoma grows and identifies a new target for treatment of melanoma and other cancers.

Released: 20-Apr-2016 9:05 AM EDT
Yale Researchers Discover Drug Target in Rare, Lethal Glandular Cancer
Yale Cancer Center/Smilow Cancer Hospital

Using a novel cell culture approach, Yale Cancer Center researchers have discovered critical vulnerabilities in adenoid cystic carcinoma (ACC), a rare and lethal glandular cancer with a high recurrence rate and few treatment options. The findings, published April 15th in the journal.

Released: 13-Jun-2016 9:00 AM EDT
From Nanotechnology, A Better Prognostic Tool For Brain Cancer
Yale Cancer Center/Smilow Cancer Hospital

A new nano-fabricated platform for observing brain cancer cells provides a much more detailed look at how the cells migrate and a more accurate post-surgery prognosis for brain cancer (glioblastoma) patients.

Release date: 30-Aug-2016 2:05 PM EDT
madhav dhodapkar receives prestigious outstanding investigator award
Yale Cancer Center/Smilow Cancer Hospital

The National Cancer Institute (NCI) has named Madhav V. Dhodapkar, MBBS, a recipient of its Outstanding Investigator Award. Dr. Dhodapkar is the Arthur H. Bunker and Isabel Bunker Professor of Medicine (Hematology), Chief of Hematology, Professor of Immunobiology, and co-Director of the Cancer Immunology Program of Yale Cancer Center. He will receive $7 million in research funding over seven years from the NCI.

Released: 14-Sep-2016 3:05 PM EDT
Yale Cancer Center Researchers Identify New T cell Subsets with Potential to Improve Cellular Therapy for Cancer
Yale Cancer Center/Smilow Cancer Hospital

A Yale Cancer Center research team has identified that two genes, NR4A1 and ABC transporters, mark a distinct subset of quiescent T cells within human tissues, and have developed methods to mobilize them into circulation for potential application in adoptive T cell therapy of cancer.

Released: 15-Sep-2016 10:05 AM EDT
New Phase I Clinical Trials Infusion Center Opens at Smilow Cancer Hospital
Yale Cancer Center/Smilow Cancer Hospital

The new Phase I Clinical Trial Infusion Center will provide essential options for patients with advanced cancers seeking new therapies when standard treatments are no longer an option.

Released: 16-Sep-2016 3:05 PM EDT
Innovation to Impact: Dr. Lieping Chen and NextCure
Yale Cancer Center/Smilow Cancer Hospital

Dr. Lieping Chen has launched a startup—NextCure—that is poised to lead to even more breakthrough treatments.

Released: 20-Sep-2016 10:05 AM EDT
Fighting Cancer with Sticky Nanoparticles
Yale Cancer Center/Smilow Cancer Hospital

A team of researchers at Yale found that a treatment using bioadhesive nanoparticles loaded with a potent chemotherapy drug proved more effective and less toxic than conventional treatments for gynecological cancer.

Released: 23-Sep-2016 1:05 PM EDT
Yale Team Compares Effectiveness of Four PD-L1 Tests
Yale Cancer Center/Smilow Cancer Hospital

In a recent study, a Yale Cancer Center team compared the performance of the four available PD-L1 assay tests. They found that one of the assays failed to reveal comparable levels of PD-L1, a tumor-promoting protein, while three others revealed comparable levels.

Released: 23-Sep-2016 2:05 PM EDT
Pembrolizumab Approval Is Tip of the Iceberg for Immunotherapy in HNSCC
Yale Cancer Center/Smilow Cancer Hospital

Immunotherapy is a big change for head and neck cancer and there seems to be no doubt that there is activity for immunotherapies with pembrolizumab as well as nivolumab [Opdivo]” said Burtness, professor of Medicine at Yale Cancer Center.

Released: 26-Sep-2016 10:05 AM EDT
Medulloblastoma Patients Should Receive Both Chemotherapy and Radiation Post-Surgery
Yale Cancer Center/Smilow Cancer Hospital

In a recent study, a Yale Cancer Center team revealed that the addition of chemotherapy to postoperative treatment for adults with medulloblastoma improves survival.

Released: 27-Sep-2016 12:05 PM EDT
Optimal Management for NSCLC Patients with Brain Metastases
Yale Cancer Center/Smilow Cancer Hospital

A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases to determine the best option for treatment.

Released: 27-Sep-2016 12:05 PM EDT
Link Between Facility Volume and Radiation Outcomes for Head and Neck Cancers
Yale Cancer Center/Smilow Cancer Hospital

The association between provider case volume and outcomes has long been suggested in cancer care. A Yale Cancer Center team has completed a review of outcomes for patients with locally advanced squamous cell head and neck cancers treated with intensity-modulated radiation therapy (IMRT) and found a distinct association between higher-volume treatment centers and improved overall survival.

Released: 27-Sep-2016 1:05 PM EDT
Radiation Boost Reduces Local Tumor Recurrence for DCIS Patients Following WBRT
Yale Cancer Center/Smilow Cancer Hospital

A supplemental “boost” of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with Ductal Carcinoma In Situ (DCIS) who receive whole breast radiation therapy radiation (WBRT) following lumpectomy, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

27-Sep-2016 2:55 PM EDT
Cardiac Risk a Factor When Considering Hormonal Therapy for Prostate Cancer
Yale Cancer Center/Smilow Cancer Hospital

In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack.

Released: 4-Oct-2016 9:05 AM EDT
Yale Study Identifies New Way to Suppress Lung Tumors
Yale Cancer Center/Smilow Cancer Hospital

A Yale-led research team has identified a new blocking mechanism that acts like a dimmer switch and inhibits lung tumor cell growth.

Released: 4-Oct-2016 9:05 AM EDT
Bladder Cancer Research Rife with New Approaches
Yale Cancer Center/Smilow Cancer Hospital

The FDA approval of Tecentriq ushered in the first new treatment for advanced bladder cancer in 30 years.

Released: 6-Oct-2016 10:05 AM EDT
Charles S. Fuchs to Lead Yale Cancer Center and Smilow Cancer Hospital
Yale Cancer Center/Smilow Cancer Hospital

After an extensive national search, Smilow Cancer Hospital and Yale Cancer Center (YCC) have announced that Charles S. Fuchs, MD, MPH, will become the new YCC director and physician-in-chief at Smilow Cancer Hospital, effective Jan. 1, 2017.


close
0.93632